Biomarkers for Oncology
JH · Effective Oct 1, 2015
208 active Medicare policies list C61, and 24 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
Showing 100 of 208
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
J5 · Effective Oct 1, 2015
J8 · Effective Oct 1, 2015
J9 · Effective Apr 11, 2016
JH · Effective Dec 1, 2016
JL · Effective Dec 1, 2016
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
24 policies from 3 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Showing 10 of 22 · All Aetna policies
| Policy | Effective | Status of C61 |
|---|---|---|
| Benign Prostatic Hyperplasia | Feb 8, 2024 | Covered |
| Brachytherapy | Jun 6, 2023 | Covered |
| Carbogen Inhalation Therapy | Jun 8, 2023 | Covered |
| Cetuximab (Erbitux) | Feb 2, 2024 | Covered |
| Flow Cytometry, Ektacytometry, DNA Ploidy, and S-phase Fraction | Jun 5, 2023 | Covered |
| Genetic Testing | Feb 27, 2024 | Covered |
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J6 · Effective Jul 15, 2026
JK · Effective Jul 15, 2026
JJ · Effective Jul 24, 2022
JM · Effective Jul 24, 2022
J15 · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
J6 · Effective Apr 1, 2019
JK · Effective Apr 1, 2019
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Jul 5, 2026
JM · Effective Jul 5, 2026
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Feb 19, 2023
JM · Effective Feb 19, 2023
J15 · Effective Sep 22, 2024
JE · Effective Sep 22, 2024
JF · Effective Sep 22, 2024
JJ · Effective Sep 22, 2024
JM · Effective Sep 22, 2024
J5 · Effective Sep 22, 2024
J8 · Effective Sep 22, 2024
J15 · Effective Aug 21, 2022
JE · Effective Aug 8, 2022
JF · Effective Aug 8, 2022
JJ · Effective Jul 3, 2022
JM · Effective Jul 3, 2022
J5 · Effective Jul 3, 2022
J8 · Effective Jul 3, 2022
J15 · Effective Dec 26, 2021
JE · Effective Jan 2, 2022
JF · Effective Jan 2, 2022
JJ · Effective Dec 26, 2021
JM · Effective Dec 26, 2021
J5 · Effective Dec 26, 2021
J8 · Effective Dec 26, 2021
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
J15 · Effective Feb 10, 2020
JE · Effective May 17, 2020
JF · Effective May 17, 2020
JJ · Effective Feb 10, 2020
JM · Effective Feb 10, 2020
J5 · Effective Feb 9, 2020
J8 · Effective Feb 9, 2020
J15 · Effective Jul 25, 2021
JE · Effective Jul 4, 2021
JF · Effective Jul 4, 2021
J5 · Effective Jul 25, 2021
J8 · Effective Jul 25, 2021
JJ · Effective Jul 25, 2021
JM · Effective Jul 25, 2021
J15 · Effective Jul 27, 2020
JE · Effective Dec 26, 2022
JF · Effective Dec 26, 2022
JJ · Effective Feb 3, 2020
JM · Effective Feb 3, 2020
J5 · Effective Mar 15, 2020
J8 · Effective Mar 15, 2020
J15 · Effective Nov 9, 2020
JE · Effective Dec 6, 2020
JF · Effective Dec 6, 2020
JJ · Effective Nov 8, 2020
JM · Effective Nov 8, 2020
J5 · Effective Nov 8, 2020
J8 · Effective Nov 8, 2020
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
| Gonadotropin-Releasing Hormone Analogs and Antagonists | Jul 14, 2023 | Covered |
|---|
| High Intensity Focused Ultrasound | Oct 11, 2023 | Covered |
|---|
| Implantable Hormone Pellets | Jul 14, 2023 | Covered |
|---|
| In Vivo Analysis of Gastro-Intestinal and Urothelial Lesions | Oct 17, 2023 | Covered |
|---|
| Policy | Effective | Status of C61 |
|---|---|---|
| Molecular and Proteomic Diagnostic Testing for Hematology and Oncology Indications | Sep 13, 2026 | Covered |
| Policy | Effective | Status of C61 |
|---|---|---|
| Denosumab | Oct 1, 2026 | Covered |